欢迎访问中国烧伤创疡杂志网站！

湿润烧伤膏治疗寻常型银屑病临床研究
Clinical Efficacy of Moist Exposed Burn Ointment in the Treatment of Psoriasis Vulgaris

陈栋,李奇俊.湿润烧伤膏治疗寻常型银屑病临床研究[J].中国烧伤创疡杂志,2025,(1):79~82.

DOI：

中文关键词: 湿润烧伤膏银屑病血管内皮生长因子异维 A 酸软胶囊肿瘤坏死因子-α

英文关键词:Moist exposed burn ointment Psoriasis vulgaris Vascular endothelial growth factor Isotretinoin soft capsule Tumor necrosis factor-α

基金项目:

作者	单位
陈栋	457001 河南濮阳, 濮阳市油田总医院皮肤科
李奇俊

摘要点击次数: 574

全文下载次数: 672

中文摘要:

【摘要】目的研究湿润烧伤膏治疗寻常型银屑病的临床疗效。方法选取 2021 年 7 月至 2023 年 4 月濮阳市油田总医院收治的 68 例中重度寻常型银屑病患者作为研究对象, 按照不同治疗方法将其分为观察组 (34例) 与对照组 (34 例)。对照组患者采用异维 A 酸软胶囊口服治疗, 观察组患者在异维 A 酸软胶囊口服基础上加用湿润烧伤膏治疗, 对比观察两组患者血清血管内皮生长因子 (VEGF) 与肿瘤坏死因子-α (TNF-α) 水平、皮损严重程度、生活质量及临床疗效。结果治疗 8 周后, 观察组患者血清 VEGF、TNF-α 水平以及银屑病皮损面积和严重性指数 (PASI) 与皮肤病生活质量指数 (DLQI) 评分均明显低于对照组 ( t = 5.047、3.921、3.539、4.236, P 均<0.001)。观察组患者临床总有效率为 94.12%, 明显高于对照组患者的临床总有效率 76.47% ( χ2 =4.221, P= 0.040)。结论湿润烧伤膏能够通过降低局部增生及炎症水平改善寻常型银屑病患者临床症状, 疗效显著。

英文摘要:

【Abstract】 Objective To study the clinical efficacy of moist exposed burn ointment (MEBO) in the treatment of psoriasis vulgaris. Methods 68 patients with moderate?severe psoriasis vulgaris admitted into Puyang Oilfield General Hospital from July 2021 to April 2023 were enrolled as research subjects and divided into the study group (n = 34) and the control group (n = 34) based on different treatment methods. Patients in the control group were treated with the oral administration of isotretinoin soft capsules while patients in the study group were treated with MEBO on the basis of oral administration of isotretinoin soft capsules. The levels of serum vascular endothelial growth factor (VEGF) and tumor necrosis factor-α (TNF-α), skin lesion severity, quality of life, and clinical efficacy of patients were compared bwtween the two groups. Results After 8 weeks of treatment, serum VEGF and TNF-α levels as well as scores of psoriasis area and severity index (PASI) and dermatology life quality index (DLQI) of patients in the study group were significantly lower than those of the control group (t = 5.047, 3.921, 3.539 and 4.236, all P<0.001). The total clinical effective rate was 94.12% in the study group, which was significantly higher than the corresponding 76.47% in the control group ( χ2 = 4.221, P = 0.040). Conclusion MEBO can effectively alleviate clinical symptoms in patients with psoriasis vulgaris by reducing the level of local proliferation and inflammation, demonstrating significant therapeutic efficacy.